

Origins of Small Proton Chemical Shift Differences in Monodeuterated Methyl Groups


O. Maduka Ogbu,[†] Stuart J. Elliott,[‡] David A. Kolin,[†] Lynda J. Brown,[‡] Sebastian Cevallos,[†] Stuart Sawyer,[‡] Malcolm H. Levitt,[‡] and Daniel J. O'Leary^{*,†}

[†]Department of Chemistry, Pomona College, 645 North College Avenue, Claremont, California 91711, United States

[‡]School of Chemistry, University of Southampton, Southampton SO17 1BJ, United Kingdom

Supporting Information

ABSTRACT: We have recently shown that the small proton chemical shift difference in 2-methyl-1-(methyl-*d*)piperidine supports a long-lived nuclear spin state. To identify additional candidate molecules with CH₂D groups exhibiting accessible long-lived states, and to investigate the factors governing the magnitude of the shift differences, we report a computational and experimental investigation of methyl rotational dynamics and proton chemical shifts in a variety of 2-substituted 1-(methyl-*d*)piperidines. The polarity and size of the 2-substituent affect the 1,2-stereoisomeric relationship and consequently the strength of the rotational asymmetry within the CH₂D group. Nonpolar and large 2-substituents prefer the equatorial position, and relatively large shift differences (i.e., > 13 ppb) are observed. Polar and small substituents, however, increasingly prefer the axial position, and medium to small shift differences (i.e., 0 to 9 ppb) are observed. In addition, diastereotopic CH₂D proton chemical shift difference for tricarbonyl(1-chloro-2-deuteriomethylbenzene) chromium(0) was computed, showing that reasonable predictions of these small shift differences can be extended to more complex, organometallic species.



INTRODUCTION

The discovery of long-lived nuclear spin states (LLS)^{1–3} in a variety of molecular systems has attracted significant interest. LLS lifetimes often surpass the characteristic relaxation time of ordinary magnetization (T_1) by an order of magnitude.² LLS are particularly promising in combination with the large sensitivity improvements afforded by NMR hyperpolarization.^{3,4a} Applications benefiting from substantial NMR signal enhancements include: imaging and monitoring of cancer in human patients,^{4a} targeting molecules relevant to neuroscience,^{4b} protein unfolding mechanisms,^{4c} and measuring slow diffusion coefficients of large biomolecules.^{4d}

The generation of long-lived states typically requires combining radiofrequency pulse sequences with chemically inequivalent and scalar coupled nuclei. The extension of these techniques to methyl groups requires CH₂D groups consisting of diastereotopic protons with different chemical shifts. For technical reasons that relate to LLS pulse sequences,^{2d,f} very small chemical shift differences (<20 ppb) were viewed as particularly ideal. We have recently shown that a LLS is supported in the monodeuterated methyl groups of two molecules: 2-methyl-1-(methyl-*d*)piperidine⁵ and tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0).⁶ Both LLS were accessed via small proton chemical shift differences (ca. 13 and 8 ppb, respectively) between the diastereotopic protons of their corresponding CH₂D groups (Figure 1).

To the best of our knowledge, there are only three reported cases shown to induce chemical shifts between diastereotopic protons of the CH₂D group,^{7–10} and little is known about the 50 factors governing the magnitude of these shift differences. In




Figure 1. Ratios of T_S , the singlet order relaxation time constant, and T_1 , the longitudinal relaxation time constant, and the small chemical shift differences ($\Delta\delta$) for the diastereotopic CH₂D protons of 2-methyl-1-(methyl-*d*)piperidine and tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0).^{5,6}

the case of 2-methyl-1-(methyl-*d*)piperidine, previous measurements and predictions by Anet and Kopelevich,⁷ and 52 computations by us,^{8,9} have shown that due to hyperconjugation effects between the lone pair of the piperidine 54 nitrogen and an *anti*-methyl C–H(D) bond, and the local chiral 55 environment around the CH₂D group, an asymmetric 56 population distribution of the three CH₂D rotamers is achieved. 57 This results in a small secondary equilibrium isotope effect and 58 corresponds to a shift difference between the CH₂D protons, 59 observed using ¹H NMR spectroscopy. 60

Encouraged by these results, we set out to explore a variety of 61 2-substituted 1-(methyl-*d*)piperidines (Figure 2). Our goal was 62 to understand how the steric and electronic nature of the 2- 63

Received: June 1, 2017

Published: July 26, 2017




Figure 2. Three CH₂D rotamers, labeled as deuterium positioned *anti* to N lone-pair (A), in steric proximity to R group (S), and relatively free from steric hindrance of R group (F) (top). The four stereoisomers of each substituted piperidine (middle). The eight 2-substituted 1-(methyl-*d*)piperidines computed in this study (bottom).

substituent perturbs the EIE and proton shift differences in this family of compounds. Through joint computational and experimental efforts, we discovered that, in general, the magnitude of chemical shift difference between CH₂D protons is affected by the preferred stereoisomeric relationship between the CH₂D group and the 2-substituent on the piperidine ring. Nonpolar and large 2-substituents prefer the equatorial position, and relatively large shift differences (i.e., > 13 ppb) are observed. Polar and small substituents, however, increasingly prefer the axial position, and medium to small shift differences (i.e., 0 to 9 ppb) are observed.

We computed the weighted average of shift differences for all populated states in each piperidine species to accurately predict proton chemical shift differences of the kind described above. To accomplish this, a gas-phase conformational search was performed using the Merck Molecular Force Field (MMFFs) as implemented in Schrödinger MacroModel suite. Quantum mechanical computations in Gaussian 09 to obtain refined structures and energies for each conformer were performed at the ω B97X/cc-pVTZ level of theory, including the polarizable continuum model (PCM) for dichloromethane. All stationary points were verified as minima by a vibrational frequency analysis. For each optimized structure, the thermochemistry of the CH₂D rotamers were obtained at the same level of theory. NMR isotropic shielding constants, and thus chemical shifts, for each structure were computed at the HF/6-311+G(2d,p) level of theory including PCM for dichloromethane. The averaged chemical shift differences were computed as the weighted sum of the chemical shift

Table 1. Mole Fractions (χ) of CH₂D Rotamers Across Stereoisomers, and Corresponding Computational (comp) and Experimental (exp) Chemical Shift Differences ($\Delta\delta$) between Prochiral CH₂D Protons (i.e., H_R and H_S, See Figure 2) in Eight 2-Substituted 1-(Methyl-*d*)piperidine Compounds^a

Entry	R	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	$\Delta\delta_{\text{comp}}$	$\Delta\delta_{\text{exp}}$
I	<i>i</i> -Pr	0.329	0.325	0.283	0.000	0.000	0.000	0.012	0.011	0.011	0.005	0.005	0.005	22.9	– ^b
II	Me	0.333	0.321	0.288	0.017	0.017	0.016	0.002	0.002	0.002	0.000	0.000	0.000	13.2	13.5 ^c
III	CF ₃	0.202	0.192	0.174	0.117	0.119	0.114	0.017	0.016	0.015	0.011	0.011	0.010	6.9	7.1
IV	Ethynyl	0.083	0.083	0.075	0.255	0.260	0.240	0.001	0.001	0.001	0.000	0.000	0.000	4.7	6.6
V	COOMe ^e	0.279	0.272	0.249	0.066	0.066	0.063	0.001	0.001	0.001	0.000	0.000	0.000	2.6	2.2
VI	F	0.001	0.001	0.001	0.336	0.338	0.323	0.000	0.000	0.000	0.000	0.000	0.000	1.3	– ^b
VII	Ph	0.000	0.000	0.000	0.228	0.229	0.216	0.000	0.000	0.000	0.110	0.110	0.107	0.3	<1
VIII	<i>t</i> -Bu	0.021	0.020	0.018	0.000	0.000	0.000	0.297	0.290	0.274	0.027	0.027	0.025	–10.2	– ^b

entry	R	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	χ^S	χ^F	χ^A	$\Delta\delta_{\text{comp}}$	$\Delta\delta_{\text{exp}}$ ^b
I	<i>i</i> -Pr	0.329	0.325	0.283	0.000	0.000	0.000	0.012	0.011	0.011	0.005	0.005	0.005	22.9	^c
II	Me	0.333	0.321	0.288	0.017	0.017	0.016	0.002	0.002	0.002	0.000	0.000	0.000	13.2	13.5 ^d
III	CF ₃	0.202	0.192	0.174	0.117	0.119	0.114	0.017	0.016	0.015	0.011	0.011	0.010	6.9	7.1
IV	Ethynyl	0.083	0.083	0.075	0.255	0.260	0.240	0.001	0.001	0.001	0.000	0.000	0.000	4.7	6.6
V	COOMe ^e	0.279	0.272	0.249	0.066	0.066	0.063	0.001	0.001	0.001	0.000	0.000	0.000	2.6	2.2
VI	F	0.001	0.001	0.001	0.336	0.338	0.323	0.000	0.000	0.000	0.000	0.000	0.000	1.3	^c
VII	Ph	0.000	0.000	0.000	0.228	0.229	0.216	0.000	0.000	0.000	0.110	0.110	0.107	0.3	<1
VIII	<i>t</i> -Bu	0.021	0.020	0.018	0.000	0.000	0.000	0.297	0.290	0.274	0.027	0.027	0.025	–10.2	^c

^aSignificant fractional populations of stereoisomers ($\chi_{S+F+A} > 0.1$) reported in bold.²⁴ ^bAll experimental ¹H spectra can be found in the Supporting Information. Experimentally determined chemical shifts reported to ± 0.4 ppb precision. ^cNot prepared. ^d $\Delta\delta_{\text{exp}}$ for 2-ethyl-1-(methyl-*d*)piperidine was also experimentally determined to be 13.7 ± 0.4 ppb. ^eMultiple conformers were computed for each stereoisomer. Reported mole fractions are from the sum of all computed conformers. $\Delta\delta_{\text{exp}}$ for ethyl 1-(methyl-*d*)piperidine-2-carboxylate was determined. Methyl derivative was computed to reduce conformational complexity.

93 difference for each rotamer in each conformer and stereo-
94 isomer.^{22,23}

95 ■ RESULTS AND DISCUSSION

96 We studied eight 2-substituted 1-(methyl-*d*)piperidines. For
97 each piperidine, four possible stereoisomers (denoted as *eq*-
98 **CH₂D-*eq*-2-R**, *eq*-**CH₂D-*ax*-2-R**, *ax*-**CH₂D-*eq*-2-R**, and *ax*-
99 **CH₂D-*ax*-2-R**) were computed, and mole fractions for the
100 three corresponding rotamers, S, F, and A were derived (Figure
101 2). A summary of our results is reported in Table 1.

102 For 2-isopropyl-1-(methyl-*d*)piperidine and 2-methyl-1-
103 (methyl-*d*)piperidine, 0.94 of the fractional population of states
104 exists as *eq*-**CH₂D-*eq*-2-R**, consistent with previous reports
105 (Table 1, entries I, II).⁹ In this stereoisomer, a rotameric
106 preference for the deuteron in position S is observed. The
107 origin of this isotope effect is primarily due to an *n* → σ^*
108 hyperconjugation interaction between the nitrogen lone-pair
109 and an *anti* C–H(D) σ bond in the CH₂D group.^{7,25} This
110 stereoelectronic effect serves to weaken the *anti* C–H(D) bond
111 relative to the *gauche* positions. Evidence of this weakening is
112 observed in the computed stretching frequencies. For example,
113 in 2-isopropyl-1-(methyl-*d*)piperidine (Table 1, entry I), the
114 computed *anti* C–H stretching frequency (2957 cm^{−1}) is
115 significantly lower than those associated with the *gauche*
116 positions (3165 cm^{−1}, asymmetrical stretch; 3112 cm^{−1},
117 symmetrical stretch). To maximize zero-point vibrational
118 stabilization in the molecule, deuterium partitions into the
119 *gauche* C–H(D) bonds (i.e., position S or F). A smaller steric
120 isotope effect, originating from interactions between the 2-
121 substituent and vicinal C–H(D), results in further sequestering
122 of deuterium into position S. Predicted $\Delta\delta$ values of 22.9 and
123 13.2 ppb are computed for 2-isopropyl and 2-methyl
124 substituted piperidines, respectively, consistent with experi-
125 ments ($\Delta\delta_{\text{exp}} = 13.5 \pm 0.4$ ppb for 2-methyl-1-(methyl-
126 *d*)piperidine).²³

127 For 2-trifluoro-1-(methyl-*d*)piperidine, the dominant frac-
128 tional population of 0.57 exists as *eq*-**CH₂D-*eq*-2-R**. However, a
129 smaller but significant fractional population of 0.35 exists as *eq*-
130 **CH₂D-*ax*-2-R** (Table 1, entry III). We attribute this
131 distribution to a competing stabilizing hyperconjugation
132 between the N lone pair and the *anti* C–C σ^* orbital at the
133 2-position (i.e., the anomeric effect,²⁶ see Figure 5). We observe
134 a weakened rotameric asymmetry, caused by a diminished lone
135 pair-CH₂D interaction, and a smaller proton chemical shift
136 difference in these species. $\Delta\delta_{\text{comp}}$ of 6.9 is computed for 2-
137 trifluoro-1-(methyl-*d*)piperidine, consistent with experiments
138 ($\Delta\delta_{\text{exp}} = 7.1 \pm 0.4$ ppb).

139 For 2-ethynyl-1-(methyl-*d*)piperidine, 2-fluoro-1-(methyl-*d*)-
140 piperidine and 2-phenyl-1-(methyl-*d*)piperidine, we observe a
141 switch in stereoisomeric preference as the dominant fractional
142 population exists as *eq*-**CH₂D-*ax*-2-R** (0.76, > 0.99, and 0.67,
143 respectively, see Table 1, entries IV, VI, and VII). Relatively
144 small $\Delta\delta_{\text{comp}}$ values of 4.7, 1.3, and 0.3 ppb are computed for 2-
145 ethynyl, 2-fluoro, and 2-phenyl substituted piperidines. The
146 $\Delta\delta_{\text{exp}}$ for 2-phenyl-1-(methyl-*d*)piperidine was not experimen-
147 tally observed, suggesting that the magnitude is <1 ppb.

148 The dominant fractional population of stereoisomers in
149 methyl 1-(methyl-*d*)piperidine-2-carboxylate exists as *eq*-
150 **CH₂D-*eq*-2-R** (Table 1, entry V) as seen in the 2-isopropyl,
151 2-methyl, and 2-trifluoromethyl substituted derivatives (Table
152 1, entries I, II, and III). However, the magnitude of computed
153 and experimentally observed $\Delta\delta$ for methyl 1-(methyl-
154 *d*)piperidine-2-carboxylate is relatively small ($\Delta\delta_{\text{comp}} = 2.6$

ppb, $\Delta\delta_{\text{exp}} = 2.2 \pm 0.4$ ppb). Measurement of such small
chemical shift differences necessitated a least-squares fitting
procedure in which the low-intensity outer lines of the AB
quartet are fit using $\Delta\delta$ and 2J as adjustable parameters. (Figure
3).²⁷ The origin of this deviation can be seen by comparing the




Figure 3. Small chemical shift difference for ethyl 1-(methyl-*d*)piperidine-2-carboxylate is estimated via a least-squares fitting of the experimental spectrum using $\Delta\delta$ (2.2 ± 0.6 ppb) and 2J (11.7 Hz) as adjustable parameters.²⁷

difference in shielding constants between a proton at the S and
F rotameric positions (i.e., $\delta_S - \delta_F$) of the dominant stereo-
isomer in the four species (Figure 4). The relatively small




Figure 4. Difference in shielding constants at the S and F positions in the dominant stereoisomer of four 2-substituted 1-(methyl-*d*)piperidine. Optimized structures are illustrated using CYLview,²⁸ with distances reported in Ångströms.²⁴

$\delta_S - \delta_F$ value for methyl 1-(methyl-*d*)piperidine-2-carboxylate
may be ascribed to a CH \cdots O interaction²⁹ between the ester
carboxyl oxygen and an N-methyl H (or D), which contributes
to deshielding effects at the S position, thereby, reducing the
overall difference in magnetic environment between the H_R and
H_S protons.³⁰

In the case of 2-*tert*-butyl-1-(methyl-*d*)piperidine, the
dominant fractional population of 0.86 exists as *ax*-**CH₂D-*eq*-
2-R** (Table 1, entry VIII). This stereoisomeric preference can

be readily explained by the difference in A-values of methyl and *tert*-butyl ring substituents.³¹ Furthermore, *eq*-CH₂D-*eq*-2-R is disfavored over the most stable stereoisomer by 2.4 kcal/mol due to a more severe *t*-Bu/Me gauche interaction. Interestingly, in the preferred stereoisomer, we still observe a rotameric preference for deuterium in the S position over the F (or A) position, suggesting that the *t*-Bu is bulky enough to affect the isotopically perturbed system as seen in previous cases above. A $\Delta\delta$ of -10.2 ppb is predicted through computations. The negative $\Delta\delta$ stems from the computed proton chemical shifts at the CH₂D rotameric positions (S, F, and A) in *ax*-CH₂D-*eq*-2-R with respect to those in *eq*-CH₂D-*eq*-2-R. In 2-*tert*-butyl-1-(methyl-*d*)piperidine, where *ax*-CH₂D-*eq*-2-R is dominant, S = 2.29, F = 1.81, and A = 2.41 ppm, while in *eq*-CH₂D-*eq*-2-R, S = 2.73, F = 1.93, and A = 1.75 ppm.²³ The shielding of A with respect to S and F in the former is switched in the latter, resulting in a switch in sign of $\Delta\delta$.

Considering the results above, we build on the model previously established for evaluating and predicting equilibrium isotope effects and diastereotopic chemical shift differences in 2-substituted 1-(methyl-*d*)piperidines. Specifically, we add that the stereoisomeric relationship between the CH₂D group and 2-substituents is crucial. Nonpolar and large alkyl substituents at the 2-position tend to favor the equatorial position. For these cases, the previously established model holds true. Polar, small groups, however, show an increased preference for the axial position due to anomeric effects. The competing orbital interaction between the lone pair on the piperidine nitrogen and the σ^* of both methyl C–H(D) and 2-C–R bonds weakens the rotameric asymmetry, leading to a reduced $\Delta\delta$ (Figure 5).




Figure 5. Qualitative model for evaluating small chemical shift differences in 2-substituted 1-(methyl-*d*)piperidines.

Next, we compute the proton chemical shift difference in the CH₂D group of tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0) (Figure 1). It is known that coordination of metals to arenes results in a dramatic withdrawal of electron density from the arene and enhanced acidity of benzylic protons.^{33,34} The Cr(CO)₃ moiety of tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0) facilitates dissociation at the benzylic group, provides facial selectivity on the arene ring, and stabilizes both benzylic cations and anions formed as reactive intermediates.^{35–37} It is conceivable that the asymmetry in the complex could be coupled with selective C–H(D) bond weakening induced by the Cr(CO)₃ moiety to generate a small but observable CH₂D proton chemical shift difference. In fact, Siegel and Restelli previously reported chirotopicity of the methyl group in tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0).¹⁰ An experimentally observed chemical shift difference

of 8.0 ± 0.4 ppb is observed in benzene between the CH₂D protons, consistent with their findings.⁶

The protocol for computing the $\Delta\delta$ in the 2-substituted 1-(methyl-*d*)piperidine study (*vide supra*) was also employed here. However, the PCM for dichloromethane was substituted with that of benzene to best align with experimental conditions. We located two isomers of tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0), one of which has a carbonyl bisecting the *ortho* methyl and chloro substituents (Table 2). A slight thermodynamic preference is observed for

Table 2. Mole Fractions (χ) of CH₂D Rotamers Across Conformers, and Corresponding Computational (comp) and Experimental (exp) Chemical Shift Differences ($\Delta\delta$) between Prochiral CH₂D Protons in Tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0)^a

χ_A	χ_B	χ_C	χ_A	χ_B	χ_C	$\Delta\delta_{\text{comp}}$	$\Delta\delta_{\text{exp}}^b$
0.125	0.122	0.116	0.218	0.214	0.205	12.1	8.0

^aAll experimental NMR spectra provided in the Supporting Information.³² ^bExperimentally determined chemical shifts reported to ± 0.4 ppb precision.

the bisecting conformer ($\Delta\Delta G = 0.3$ kcal/mol). However, both conformers are predicted to equilibrate readily at room temperature ($\Delta G^\ddagger = 2.1$ kcal/mol from lowest energy conformer).²³ When computing $\Delta\delta$, we included the weighted chemical shift of the rotamers in each conformer. A $\Delta\delta$ of 12.1 ppb is predicted, in reasonable agreement with experiments.

CONCLUSION

In conclusion, we have shown that in the 2-substituted 1-(methyl-*d*)piperidine family, stereoelectronic effects of the 2-substituents on the piperidine ring strongly influence proton chemical shift differences. The polarity and size of the 2-substituent affects the 1,2-stereoisomeric relationship and consequently the strength of the rotational asymmetry within the CH₂D group. Furthermore, our tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0) results suggest that computational predictions of these small proton shift differences can be extended to a wider variety of CH₂D-containing compounds. We continue to investigate related species in our laboratories, and hope that this study aids the future synthesis and development of molecular agents bearing accessible long-lived states.

EXPERIMENTAL SECTION

General. Chemicals including labeled materials were purchased from Aldrich Chemical Co. and used without further purification. All reactions were performed in an inert argon or nitrogen atmosphere. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ or D₂O solution using a Bruker DPX 400 (400 and 101 MHz respectively) spectrometers. All spectra were reprocessed using ACD/Laboratories software version: 2014. Electron impact (EI) low-resolution mass spectra were recorded on a Trace 2000 Series GC-MS. Electrospray (ES) low-resolution mass spectra were recorded on a Waters ZMD or Waters TQD quadrupole spectrometer. Newly developed syntheses of

261 2-ethynylpiperidine³⁸ and 2-phenylpiperidine,³⁹ both known com-
262 pounds, will be reported elsewhere.

263 **2-Ethyl-1-(methyl-*d*)piperidine.** To 2-ethylpiperidine (500 mg,
264 4.42 mmol) was added formaldehyde (1.08 mL of 37 wt % in H₂O,
265 568 mg, 13.2 mmol, 3.0 equiv) followed by careful addition of formic
266 acid-*d*₂ (0.83 mL of 95% in D₂O, 22.0 mmol, 5.0 equiv), and the
267 reaction heated at 85 °C (using a water bath) for 3 h. The reaction was
268 cooled to rt, water (4 mL) added, and the acidic aqueous reaction was
269 extracted with pet. ether. The aqueous layer was basified to pH 12
270 using 6 M NaOH and extracted with Et₂O (× 5). The combined Et₂O
271 extractions were dried (MgSO₄) and concentrated on a rotary
272 evaporator without vacuum (bath temp = 40 °C) to give the title
273 compound as a pale yellow clear oil (447 mg, 3.49 mmol, 79%). ¹H
274 NMR (400 MHz, CDCl₃) δ 2.85 (br d, *J* = 11.5 Hz, 1H), 2.28–2.15
275 (m, 2H), 2.11–2.01 (m, 1H), 1.82–1.68 (m, 2H), 1.68–1.53 (m, 4H),
276 1.46–1.35 (m, 1H), 1.34–1.18 (m, 2H), 0.88 (t, *J* = 7.4 Hz, 3H) ppm;
277 ¹³C NMR (101 MHz, CDCl₃) δ 65.0, 57.3, 42.7 (t, *J*_{D,C} = 20.54 Hz,
278 CH₂D), 30.1, 26.0, 25.5, 24.5, 9.4 ppm; MS EI (*m/z*) 84.04
279 [C₈H₁₀N⁺] (70%) 49.1 (100%). HRMS (ES⁺) for C₈H₁₇DN
280 calculated 129.1497, found 129.1497 Da.

281 **2-Methyl-1-(methyl-*d*)piperidine.** To 2-methylpiperidine (844
282 mg, 1.00 mL, 8.51 mmol) was added formaldehyde (37 wt % in H₂O,
283 2.07 mL, 25.5 mmol, 3.0 equiv) followed by careful addition of formic
284 acid-*d*₂ (95% in D₂O, 1.72 g, 1.41 mL, 34.0 mmol, 4.0 equiv), and the
285 reaction heated at 85 °C (using a water bath) for 3 h. The reaction was
286 cooled to rt, water (2 mL) was added, and the acidic aqueous reaction
287 was extracted with pet. ether. The aqueous layer was basified to pH 12
288 using 6 M NaOH and extracted with Et₂O (× 5). The combined Et₂O
289 extractions were dried (MgSO₄) and concentrated on a rotary
290 evaporator without vacuum (bath temp = 40 °C) to give a pale yellow
291 oil. Purification by Kugelrohr distillation (oven temperature 150–160
292 °C) to give the title compound as a clear oil (696 mg, 6.09 mmol,
293 72%). ¹H NMR (400 MHz, CDCl₃) δ 2.80–2.76 (m, 1H), 2.18 (d,
294 *J*_{HD} = 1.0 Hz, 2H), 2.01–1.95 (m, 1H), 1.88–1.80 (m, 1H), 1.70–
295 1.48 (m, 4H), 1.29–1.16 (m, 2H), 1.04 (d, *J* = 6.1 Hz, 3H) ppm; ¹³C
296 NMR (101 MHz, CDCl₃) δ 59.3, 57.0, 42.9 (t, *J*_{D,C} = 20.5 Hz, CH₂D),
297 34.6, 26.1, 24.5, 20.2 ppm. MS EI (*m/z*) 84.07 [C₅H₁₀N⁺] (60%).

298 **2-Trifluoromethyl-1-(methyl-*d*)piperidine.** To 2-trifluorome-
299 thylpiperidine (970 mg, 6.33 mmol), was added formaldehyde (1.54
300 mL of 37% in H₂O, 18.99 mmol, 3.0 equiv) followed by careful
301 addition of formic acid-*d*₂ (1.2 mL, 31.7 mol, 5.0 equiv). The reaction
302 was heated at 85 °C (using a water bath) for 4 h before being cooled
303 to rt. Water (2 mL) was added and the acidic aqueous reaction
304 extracted with pet. ether. The aqueous layer was basified to pH 12
305 using 6 M NaOH and extracted with Et₂O (× 5). The combined Et₂O
306 extractions were dried (Na₂SO₄) and concentrated on a rotary
307 evaporator without vacuum (bath temp = 40 °C). This gave the title
308 compound as a colorless oil (948 mg, 5.64 mmol, 89%). ¹H NMR
309 (400 MHz, CDCl₃) δ 2.89 (dq, *J* = 11.9, 4.3 Hz, 1H), 2.68–2.59 (m,
310 1H), 2.39 (q, *J* = 1.8 Hz, 2H), 2.27 (dt, *J* = 11.8, 6.8 Hz, 1H), 1.88–
311 1.82 (m, 1H), 1.78–1.71 (m, 1H), 1.66–1.55 (m, 3H), 1.37–1.27 (m,
312 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 126.7 (q, *J* = 285.4 Hz),
313 63.9 (q, *J* = 25.7 Hz), 55.7, 44.0 (tq, *J* = 20.5, 2.2 Hz), 25.2 (q, *J* = 3.0
314 Hz), 25.0, 22.3 ppm; ¹⁹F NMR (376 MHz, CDCl₃) δ 68.4 ppm; MS
315 ESI⁺ (*m/z*) 169.28 [M + H]⁺. HRMS (ES⁺) for C₇H₁₂DF₃N calculated
316 169.1057, found 169.1059 Da.

317 **2-Ethynyl-1-(methyl-*d*)piperidine.** To 2-ethynylpiperidine (70
318 mg, 0.64 mmol) was added formaldehyde (157 μL of 37 wt % in H₂O,
319 58 mg, 1.93 mmol, 3.0 equiv) followed by careful addition of formic
320 acid-*d*₂ (120 μL of 95% in D₂O, 3.20 mmol, 5.0 equiv), and the
321 reaction heated at 85 °C (using a water bath) for 3 h. The reaction was
322 cooled to rt, water (1 mL) added, and the acidic aqueous reaction was
323 extracted with pet. ether. The aqueous layer was basified to pH 12
324 using 6 M NaOH and extracted with Et₂O (× 5). The combined Et₂O
325 extractions were dried (MgSO₄) and concentrated on a rotary
326 evaporator without vacuum (bath temp = 40 °C) to give the title
327 compound as a pale yellow oil (67 mg, 0.54 mmol, 85%). ¹H NMR
328 (400 MHz, CDCl₃) δ 3.42–3.33 (m, 1H), 2.63–2.48 (m, 1H), 2.37–
329 2.27 (m, 4H), 1.87–1.71 (m, 2H), 1.68–1.42 (m, 4H) ppm; MS EI
330 (*m/z*) 124.00 [M⁺] (20%). ¹³C NMR (101 MHz, CDCl₃) δ 77.2,

73.5, 68.0, 53.8, 43.9 (t, *J*_{D,C} = 20.5 Hz, CH₂D), 31.5, 25.6, 20.5 ppm; 331
MS EI (*m/z*) 124.00 [M⁺] (20%). HRMS (ES⁺) for C₈H₁₃DN 332
calculated 125.1184, found 125.1183 Da.

333 **Ethyl 1-(Methyl-*d*)piperidine-2-carboxylate.** To ethylpiperidol- 334
nate (980 mg, 6.24 mmol) was added formaldehyde (1.50 mL of 37 wt 335
% in H₂O, 568 mg, 19.08 mmol, 3.0 equiv) followed by careful 336
addition of formic acid-*d*₂ (1.20 mL of 95% in D₂O, 31.80 mmol, 5.0 337
equiv), and the reaction heated at 85 °C (using a water bath) for 3 h. 338
The reaction was cooled to rt, water (2 mL) added, and the acidic 339
aqueous reaction was extracted with pet. ether. The aqueous layer was 340
basified to pH 12 using 6 M NaOH and extracted with Et₂O (× 5). 341
The combined Et₂O extractions were dried (MgSO₄) and concen- 342
trated on a rotary evaporator without vacuum (bath temp = 40 °C) to 343
give the title compound as a clear oil (977 mg, 5.68 mmol, 91%). ¹H 344
NMR (400 MHz, CDCl₃) δ 4.18 (q, *J* = 7.1 Hz, 2H), 3.00–2.84 (m, 345
1H), 2.68 (dd, *J* = 10.3, 3.2 Hz, 1H), 2.20 (br s, 2H), 2.13–1.96 (td, *J* 346
= 11.2, 3.9 Hz, 1H), 1.86–1.55 (m, 5H), 1.34–1.23 (m, 1H), 1.25 (t, *J* 347
= 7.1 Hz, 3H) ppm; ¹³C NMR (101 MHz, CDCl₃) δ 173.5, 67.9, 60.5, 348
55.0, 43.9 (t, *J*_{D,C} = 20.5 Hz, CH₂D), 29.7, 25.1, 22.9, 14.2 ppm; MS 349
ESI⁺ (*m/z*) 173.3 [M + H]⁺. HRMS (ES⁺) for C₉H₁₇DNO₂ calculated 350
173.1395, found 173.1395 Da. 351

352 **2-Phenyl-1-(methyl-*d*)piperidine.** To 2-phenylpiperidine (1.00 352
g, 6.21 mmol), formaldehyde (1.51 mL of 37% in H₂O, 18.63 mmol, 353
3.0 equiv) was added followed by careful addition of formic acid-*d*₂ 354
(1.17 mL of 95% in D₂O, 31.05 mmol, 5.0 equiv). The reaction was 355
heated at 85 °C (using a water bath) for 4 h before being cooled to rt. 356
Water (2 mL) was added and the acidic aqueous reaction was 357
extracted with pet. ether. The aqueous layer was basified to pH 12 358
using 6 M NaOH and extracted with Et₂O (× 5). The combined Et₂O 359
extractions were dried (Na₂SO₄) and concentrated on a rotary 360
evaporator without vacuum (bath temp = 40 °C). This gave the title 361
compound as a yellow oil (921 mg, 5.23 mmol, 84%). ¹H NMR (400 362
MHz, CDCl₃) δ 7.28–7.18 (m, 5H), 2.99 (br d, 1H, *J* = 11.6), 2.71 363
(dd, 1H, *J* = 11.0, 3.0 Hz), 2.10–2.05 (m, 1H), 1.95 (s, 2H), 1.83– 364
1.12 (m, 6H) ppm; ¹³C NMR (101 MHz, CDCl₃) δ 144.9, 128.4, 365
127.4, 126.9, 71.2, 57.5, 45.6 (t, *J*_{D,C} = 20.5 Hz, CH₂D), 35.9, 26.2, 25.0 366
ppm; MS ESI⁺ (*m/z*) 177.3 [M + H]⁺. HRMS (ES⁺) for C₁₂H₁₇DN 367
calculated 177.1497, found 177.1499 Da. 368

369 **α-Deuterio-*o*-chlorotoluene.**⁴⁰ To 2-chlorobenzyl bromide 369
(2.00 g, 9.73 mmol) in DMSO-*d*₆ (6 mL) at 0 °C was added sodium 370
borodeuteride (0.82 g, 19.46 mmol) portion-wise. The reaction 371
formed a white solid that was stirred for 4 h at rt. The reaction was 372
quenched with methanol (0.75 mL), Et₂O was added, and the organic 373
layer washed with H₂O (× 3), brine and then dried (MgSO₄). The 374
solvent was removed *in vacuo* at rt. The resultant oil was purified by 375
Kugelrohr distillation to give the title compound as a colorless oil 376
(0.89 g, 6.98 mmol, 72%). Bpt 157–159 °C. ¹H NMR (400 MHz, 377
CDCl₃) δ = 7.36 (dd, *J* = 7.1, 1.7 Hz, 1H), 7.27–7.12 (m, 3H), 2.41– 378
2.37 (t, *J*_{HD} = 7.1 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 136.0, 379
134.4, 130.9, 129.0, 127.1, 126.5, 19.7 ppm (t, *J*_{CD} = 19.8 Hz). GC-MS 380
(EI) *m/z* (100%) 126.8 C₇H₆DCl⁺, 91.9 C₇H₆D⁺. 381

382 **Tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium-** 382
(0).⁴¹ α-Deuterio-*o*-chlorotoluene (1, 0.38 g, 3.0 mmol) and 383
hexacarbonyl chromium(0) (0.33 g, 1.5 mmol) in dibutyl ether/ 384
THF (9:1, 7.5 mL) was heated at reflux for 36 h. The reaction was 385
allowed to cool, Et₂O was added, and the solution passed through a 386
short column of alumina, eluting with Et₂O. The solvent was removed 387
in vacuo and the crude yellow solid recrystallized from Et₂O/pentane 388
and the yellow crystals washed with cold pentane. The title compound 389
was obtained as a yellow crystalline solid (0.28 g, 1.06 mmol, 35%). 390
Mpt 100–102 °C. ¹H NMR (400 MHz, C₆D₆) δ = 4.75 (br d, *J* = 6.2 391
Hz, 1H), 4.30 (br d, *J* = 6.0 Hz, 1H), 4.18 (br t, *J* = 6.1 Hz, 1H), 4.07 392
(br t, *J* = 6.1 Hz, 1H), 1.71 (br s, 2H); ¹³C NMR (101 MHz, C₆D₆) δ 393
= 112.0, 106.3, 93.9, 93.3, 91.0, 90.4, 19.0 ppm (t, *J*_{CD} = 19.9 Hz). GC- 394
MS (EI) *m/z* (100%) 126.8 C₇H₆DCl⁺. 395

396 **Sample Preparation.** 2-Substituted 1-(methyl-*d*)-piperidines were 396
dissolved in 0.5 mL of CD₂Cl₂ to a concentration of 0.1 M. 12.58 mg 397
of tricarbonyl(1-chloro-2-deuteriomethylbenzene)chromium(0) was 398
dissolved in 0.5 mL of C₆D₆ to a concentration of 0.1 M. TMS 399
vapor was added to all samples as a reference compound. 400

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.7b01356.

Computational protocols, benchmark studies, shielding constants, coordinates, energies, vibrational frequencies, experimental ^1H , ^{13}C , and, where appropriate, ^{19}F NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*daniel.o'leary@pomona.edu

ORCID

O. Maduka Ogba: 0000-0002-5718-6761

Malcolm H. Levitt: 0000-0001-9878-1180

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

O.M.O., D.A.K., S.C., and D.J.O. acknowledge support from Pomona College. S.J.E., L.J.B., S.S., and M.H.L. acknowledge support from the Engineering and Physical Sciences Research Council (UK), grant codes EP/N002482 and EP/L505067/1, the Wolfson Foundation, and Bruker Biospin (UK).

■ REFERENCES

- (1) For recent reviews of LLS, see: (a) Pileio, G. *Prog. Nucl. Magn. Reson. Spectrosc.* **2017**, 98–99, 1–19. (b) Levitt, M. H. *Annu. Rev. Phys. Chem.* **2012**, 63 (1), 89–105.
- (2) (a) Stevanato, G.; Hill-Cousins, J. T.; Hakansson, P.; Roy, S. S.; Brown, L. J.; Brown, R. C. D.; Pileio, G.; Levitt, M. H. *Angew. Chem., Int. Ed.* **2015**, 54, 3740–3743. (b) Pileio, G.; Dumez, J.-N.; Pop, I.-A.; Hill-Cousins, J. T.; Brown, R. C. D. *J. Magn. Reson.* **2015**, 252, 130–134. (c) Dumez, J.-N.; Hill-Cousins, J. T.; Brown, R. C. D.; Pileio, G. *J. Magn. Reson.* **2014**, 246, 27–30. (d) DeVience, S. J.; Walsworth, R. L.; Rosen, M. S. *Phys. Rev. Lett.* **2013**, 111 (17), 173002. (e) Feng, Y.; Davis, R. M.; Warren, W. S. *Nat. Phys.* **2012**, 8, 831–837. (f) Tayler, M. C. D.; Levitt, M. H. *Phys. Chem. Chem. Phys.* **2011**, 13 (13), 5556–5560. (g) Pileio, G.; Carravetta, M.; Levitt, M. H. *Proc. Natl. Acad. Sci. U. S. A.* **2010**, 107 (40), 17135–17139. (h) Warren, W. S.; Jenista, E.; Branca, R. T.; Chen, X. *Science* **2009**, 323 (5922), 1711–1714. (i) Pileio, G.; Carravetta, M.; Hughes, E.; Levitt, M. H. *J. Am. Chem. Soc.* **2008**, 130, 12582–12583. (j) Carravetta, M.; Johannessen, O. G.; Levitt, M. H. *Phys. Rev. Lett.* **2004**, 92, 153003.
- (3) (a) Ji, X.; Bornet, A.; Vuichoud, B.; Milani, J.; Gajan, D.; Rossini, A. J.; Emsley, L.; Bodenhausen, G.; Jannin, S. *Nat. Commun.* **2017**, 8, 13975. (b) Rodrigues, T. B.; Serrao, E. M.; Kennedy, B. W. C.; Hu, D.-E.; Kettunen, M. I.; Brindle, K. M. *Nat. Med.* **2013**, 20 (1), 93–97. (c) Ardenkjaer-Larsen, J.-H.; Fridlund, B.; Gram, A.; Hansson, G.; Hansson, L.; Lerche, M. H.; Servin, R.; Thaning, M.; Golman, K. *Proc. Natl. Acad. Sci. U. S. A.* **2003**, 100, 10158–10163.
- (4) For applications of hyperpolarization, see: (a) Nelson, S. J.; Kurhanewicz, J.; Vigneron, D. B.; Larson, P. E. Z.; Harzstark, A. L.; Ferrone, M.; van Criekinge, M.; Chang, J. W.; Bok, R.; Park, I.; Reed, G.; Carvajal, L.; Small, E. J.; Munster, P.; Weinberg, V. K.; Ardenkjaer-Larsen, J. H.; Chen, A. P.; Hurd, R. E.; Odegardstuen, L.-I.; Robb, F. J.; Tropp, J.; Murray, J. A. *Sci. Transl. Med.* **2013**, 5 (198), 198ra108–198ra108. (b) DeVience, S. J.; Walsworth, R. L.; Rosen, M. S. *NMR Biomed.* **2013**, 26 (10), 1204–1212. (c) Bornet, A.; Ahuja, P.; Sarkar, R.; Fernandes, L.; Hadji, S.; Lee, S. Y.; Haririnia, A.; Fushman, D.; Bodenhausen, G.; Vasos, P. R. *ChemPhysChem* **2011**, 12 (15), 2729–2734. (d) Ahuja, P.; Sarkar, R.; Vasos, P. R.; Bodenhausen, G. *J. Am. Chem. Soc.* **2009**, 131 (22), 7498–7499.
- (5) Elliott, S. J.; Brown, L. J.; Dumez, J.-N.; Levitt, M. H. *Phys. Chem. Chem. Phys.* **2016**, 18 (27), 17965–17972.
- (6) Elliott, S. J.; Brown, L. J.; Dumez, J.-N.; Levitt, M. H. *J. Magn. Reson.* **2016**, 272, 87–90.
- (7) Anet, F. A. L.; Kopelevich, M. *J. Am. Chem. Soc.* **1989**, 111 (9), 3429–3431.
- (8) Allen, B. D.; O'Leary, D. J. *J. Am. Chem. Soc.* **2003**, 125 (30), 9018–9019.
- (9) Allen, B. D.; Cintrat, J.-C.; Faucher, N.; Berthault, P.; Rousseau, B.; O'Leary, D. J. *J. Am. Chem. Soc.* **2005**, 127 (1), 412–420.
- (10) Restelli, A.; Siegel, J. S. *J. Am. Chem. Soc.* **1992**, 114 (3), 1091–1092.
- (11) Lodewyk, M. W.; Siebert, M. R.; Tantillo, D. J. *Chem. Rev.* **2012**, 112 (3), 1839–1862.
- (12) Halgren, T. A. *J. Comput. Chem.* **1996**, 17 (5–6), 490–519.
- (13) *Schrodinger Release 2014–3: MacroModel*; Schrödinger, LLC: New York, NY, 2014.
- (14) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; A. F. Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, Jr., J. A.; J. E. Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Keith, T.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, O.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. *Gaussian 09*; Gaussian, Inc.: Wallingford, CT, 2009.
- (15) Chai, J.-D.; Head-Gordon, M. *J. Chem. Phys.* **2008**, 128 (8), 084106.
- (16) Dunning, T. H., Jr. *J. Chem. Phys.* **1989**, 90 (2), 1007–1023.
- (17) Miertsu, S.; Scrocco, E.; Tomasi, J. *Chem. Phys.* **1981**, 55 (1), 117–129.
- (18) Slater, J. C. *Phys. Rev.* **1951**, 81 (3), 385–390.
- (19) Ditchfield, R.; Hehre, W. J.; Pople, J. A. *J. Chem. Phys.* **1971**, 54 (2), 724–728.
- (20) Hariharan, P. C.; Pople, J. A. *Theor. Chim. Acta* **1973**, 28 (3), 213–222.
- (21) Extensive benchmark of employed theoretical method was performed. See [Supporting Information](#) for more details.
- (22) Isotopic NMR shifts calculated using the Onyx program: Brueckner, A. C.; Cevallos, S. L.; Ogba, O. M.; Walden, D. M.; Meyer, M. P.; O'Leary, D. J.; Cheong, P. H.-Y. *Onyx*, version 1.0; Oregon State University: Corvallis, OR, USA & Pomona College: Claremont, CA, USA, 2016.
- (23) See [Supporting Information](#) for more details.
- (24) Quantum mechanical structures were optimized at 25 °C in $\omega\text{B97X/cc-pVTZ/PCM(DCM)}$, NMR single points in $\text{HF/6-311+G(2d,p)/PCM(DCM)}$.
- (25) Anet, F. A. L.; Kopelevich, M. *J. Chem. Soc., Chem. Commun.* **1987**, 0 (8), 595–597.
- (26) Erxleben, N. D.; Kedziora, G. S.; Urban, J. J. *Theor. Chem. Acc.* **2014**, 133 (7), 1491.
- (27) Experimental spectrum was fitted using the *Mathematica* based NMR software package *SpinDynamica*. *SpinDynamica* Code for *Mathematica*, Programmed by Malcolm H. Levitt, with Contributions by Jyrki Rantaharju, Andreas Brinkmann, and Soumya Singha Roy. <<http://www.spindynamica.soton.ac.uk>>.
- (28) Legault, C. Y. *CYLview*, 1.0b; Université de Sherbrooke, 2009 (<http://www.cylview.org>).
- (29) (a) Sandoval-Lira, J.; Fuentes, L.; Quintero, L.; Höpfl, H.; Hernández-Pérez, J. M.; Terán, J. L.; Sartillo-Piscil, F. *J. Org. Chem.* **2015**, 80 (9), 4481–4490. (b) Scheiner, S. *Phys. Chem. Chem. Phys.* **2011**, 13 (31), 13860–13872. (c) Cannizzaro, C. E.; Houk, K. N. *J. Am. Chem. Soc.* **2002**, 124 (24), 7163–7169. (d) Corey, E. J.; Rohde, J.

- 532 J. *Tetrahedron Lett.* **1997**, 38 (1), 37–40. For CH...O reviews, see:
533 (e) Desiraju, G. R. *Acc. Chem. Res.* **1996**, 29 (9), 441–449.
534 (f) Johnston, R. C.; Cheong, P. H.-Y. *Org. Biomol. Chem.* **2013**, 11
535 (31), 5057–5064.
536 (30) H₂CH...FCF₂ contacts are observed in the dominant stereo-
537 isomer of N-CH₂D-2-trifluoromethylpiperidine. However, this is not
538 expected to be stabilizing and hence, not contribute to deshielding
539 effects at the S position. For a detailed study of CH...F interactions,
540 see: Kryachko, E.; Scheiner, S. J. *Phys. Chem. A* **2004**, 108 (13), 2527–
541 2535.
542 (31) Hirsch, J. A. In *Topics in Stereochemistry*; Allinger, N. L., Eliel, E.
543 L., Eds.; John Wiley & Sons, Inc., 1967; pp 199–222.
544 (32) Quantum mechanical structures were optimized at 25 °C in
545 ωB97X/cc-pVTZ/PCM(benzene), NMR single points in HF/6-
546 311+G(2d,p)/PCM(benzene).
547 (33) Semmelhack, M. F.; Yamashita, A. *J. Am. Chem. Soc.* **1980**, 102
548 (18), 5924–5926.
549 (34) Trahanovsky, W. S.; Card, R. J. *J. Am. Chem. Soc.* **1972**, 94 (8),
550 2897–2898.
551 (35) Merlic, C. A.; Walsh, J. C.; Tantillo, D. J.; Houk, K. N. *J. Am.*
552 *Chem. Soc.* **1999**, 121 (15), 3596–3606.
553 (36) Davies, S. G.; Donohoe, T. J. *Synlett* **1993**, 1993 (05), 323–332.
554 (37) Uemura, M. In *Organic Reactions*; John Wiley & Sons, Inc.,
555 2004.
556 (38) Lundkvist, J. R. M.; Vargas, H. M.; Caldirola, P.; Ringdahl, B.;
557 Hacksell, U. *J. Med. Chem.* **1990**, 33 (12), 3182–3189.
558 (39) Prokopcová, H.; Bergman, S. D.; Aelvoet, K.; Smout, V.;
559 Herrebout, W.; Van der Veken, B.; Meerpoel, L.; Maes, B. U. W.
560 *Chem. - Eur. J.* **2010**, 16 (44), 13063–13067.
561 (40) Hutchins, R. O.; Kandasamy, D.; Dux, F.; Maryanoff, C. A.;
562 Rotstein, D.; Goldsmith, B.; Burgoyne, W.; Cistone, F.; Dalessandro,
563 J.; Puglis, J. *J. Org. Chem.* **1978**, 43 (11), 2259–2267.
564 (41) Hörstermann, D.; Schmalz, H.-G.; Kociok-Köhn, G. *Tetrahedron*
565 **1999**, 55 (22), 6905–6916.